TD Private Client Wealth LLC Sells 11,652 Shares of Medtronic PLC $MDT

TD Private Client Wealth LLC lessened its position in Medtronic PLC (NYSE:MDT) by 9.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 106,274 shares of the medical technology company’s stock after selling 11,652 shares during the period. TD Private Client Wealth LLC’s holdings in Medtronic were worth $10,122,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Riverbend Wealth Management LLC increased its position in shares of Medtronic by 3.2% in the 3rd quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after buying an additional 107 shares in the last quarter. Wynn Capital LLC grew its stake in Medtronic by 2.4% in the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after acquiring an additional 110 shares during the period. Meridian Investment Counsel Inc. increased its holdings in shares of Medtronic by 0.4% in the third quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after acquiring an additional 110 shares in the last quarter. Saxony Capital Management LLC raised its position in shares of Medtronic by 3.8% during the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock worth $290,000 after purchasing an additional 112 shares during the period. Finally, Cape Investment Advisory Inc. lifted its holdings in shares of Medtronic by 3.2% during the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after purchasing an additional 113 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Stock Down 0.6%

Medtronic stock opened at $96.92 on Tuesday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company has a fifty day simple moving average of $98.44 and a 200 day simple moving average of $94.65. The company has a market cap of $124.26 billion, a P/E ratio of 26.13, a price-to-earnings-growth ratio of 2.57 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same period last year, the company earned $1.26 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MDT. Cowen reissued a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Citigroup upped their price target on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Daiwa Capital Markets increased their price objective on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Finally, Wells Fargo & Company increased their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).